A cross-institution team led by Mass General Brigham, Dana-Farber Cancer Institute, and the Broad Institute identified a novel immune evasion mechanism in acute myeloid leukemia involving the glycoprotein CD43, reported in Science. The work reframes CD43 as part of a “don’t-eat-me” axis that helps AML cells avoid clearance by immune effectors. The study connects mechanism with potential therapeutic targeting by showing how altering the relevant biology can disrupt leukemia immune escape. The finding matters for AML drug development because checkpoint-like escape pathways remain attractive targets where conventional immunotherapies often underperform. For biotech, the CD43 linkage provides a new mechanistic handle for next-generation immune strategies, including combinations with existing AML therapies designed to enhance immune recognition and killing.